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RAPID COMMUNICATION
Sustained expression of TGF-f31 underlies development of
progressive kidney fibrosis
TATSUO YAMAMOTO, NANCY A. NOBLE, DIANE E. MILLER, and WAYNE A. BORDER
Division of Nephrology, University of Utah School of Medicine, Salt Lake City, Utah, USA
Sustained expression of TGF-fl underlies development of progressive
kidney fibrosis. We found that TGF-pl expression and increased matrix
production is transient and self-limited in nephritic glomeruli from rats
with acute, reversible glomerulonephritis induced by a single injection
of an antibody reactive with glomerular mesangial cells. In contrast, in
rats given a second antibody injection, one week later, the glomerular
expression of TGF-13l mRNA and TGF-/3l protein remained elevated
through 18 weeks and was associated with a large infiltration of
mononuclear cells, with staining features of fibroblastic/myofibroblastic
cells, strongly expressing TGF-pl in the tubulointerstitium of the
kidney. By 18 weeks kidneys from animals receiving two antibody
injections showed glomerulosclerosis and tubulointerstitial fibrosis with
striking deposition of collagens type I and III, whereas kidney tissue
from animals given one antibody injection was indistinguishable from
normal control. The histological changes were accompanied by persis-
tent proteinuria and elevated levels of blood urea nitrogen. Extracellu-
lar matrix markers of TGF-/31 activity, a special isoform of fibronectin,
tenascin, biglycan and plasminogen activator inhibitor-l, were signifi-
cantly elevated in kidneys undergoing fibrosis. These data suggest that
sustained TGF-/31 expression contributes to the development of pro-
gressive kidney fibrosis.
A central pathological feature of progressive glomerular
disorders resulting in end-stage kidney disease is development
of glomerulosclerosis, caused by pathological accumulation of
extracellular matrix [1, 2]. Intriguingly, glomeruloscierosis is
accompanied by development of progressive fibrosis in tubu-
lointerstitial regions of the kidney. Several studies have shown
that in many forms of chronic glomerular disease, the severity
of tubulointerstitial fibrosis correlates better with kidney func-
tion than does the severity of glomerulosclerosis [4—9]. The
molecular mechanism(s) linking glomerular injury to tubuloin-
terstitial fibrosis is unknown [10].
Previously, we reported that the production of TGF-/31
underlies the accumulation of glomerular extracellular matrix in
rats with experimental glomerulonephritis induced by a single
injection of an antiserum that reacts with a Thy-i-like antigen
on the surface of glomerular mesangial cells [11]. Injection of
the anti-mesangial serum (AMS) into rats produces a dose and
complement dependent, direct and selective injury to mesangial
cells and acute mesangial proliferative glomerulonephritis [12,
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13]. Following injury, the glomeruli greatly increased the ex-
pression of TGF-31 mRNA and TGF-j31 protein which was
accompanied by a striking increase in production of fibronectin
and proteoglycans. These events coincided with a marked
decrease in glomerular plasminogen activator activity and an
increase in synthesis and deposition of plasminogen activator
inhibitor-i (PA!-!) in the diseased glomeruli [14]. The plasmin-
ogen/plasmin protease system is considered to play a key role in
matrix degradation and turnover. Administration of an anti-
serum capable of neutralizing TGF-f31 activity suppressed the
overproduction of matrix components by the nephritic glomer-
uli, decreased the deposition of PA!-!, and greatly attenuated
histological manifestations of the disease [14, 15]. TGF-/31
added to normal glomeruli also increases the expression of
a5131, an integrin receptor for fibronectin, while nephritic
glomeruli show large increases in aSl that correlate with
increased fibronectin deposition into the matrix [16]. Thus the
pathological accumulation of glomerular matrix in this model
was shown to be due to both increased production and de-
creased removal of matrix and modulation of an integrin recep-
tor in a manner that could enhance matrix deposition—all under
the influence of TGF-f31.
In our study, following a single episode of immune injury
induced by injection of AMS, TGF-/31 expression in the gb-
meruli along with increased production of matrix components
reached a peak at two weeks and returned to basal level by four
weeks [11]. Simultaneously the pathological matrix began to
regress and the gbomeruli returned to a histologically normal
appearance. In contrast to the self-limited and reversible dis-
ease observed after one AMS injection, repeated injections of
AMS are reported to produce chronic disease [17, 18]. Since we
previously found a close correlation between disease activity
and TGF-ffl expression in the single injection model, we
hypothesized that sustained TGF-/3! expression might also
underlie development of chronic disease. To test the hypothesis
we investigated the effect of one versus two injections of AMS
on TGF-j31 expression in the model.
We report here that in animals receiving a second injection of
AMS, glomeruli show persistent TGF-/31 expression which,
unlike the single injection model, does not terminate and is
accompanied by appearance of mononuclear cells in the tubu-
lointerstitium of the kidney strongly expressing TGF-131 mRNA
and TGF-f31 protein. Elevated expression of TGF-/31 in the
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Fig. 1. Proteinuria during the course of experimental glomerulonephri-
ils. The 24-hour urinary protein excretion was measured at each time
point in (•) animals injected twice with AMS (group 1), (•) once with
AMS (group 2) and (A) control (group 3). * P < 0.03 compared to
control; *** p < 0.03 compared to 1 injection of AMS. Values are mean
SE.
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Fig. 2. Extracellular matrix in experimental glomerulonephritis. The
percent of (A) glomerular and (B) tubulointerstitial areas occupied by
matrix was quantitated by light microscopy during the course of
glomerulonephritis induced by, (dark bars) 2 injections of AMS,
(hatched bars) 1 injection of AMS and (clear bars) control. * P < 0.01
compared to control; ** P < 0.01 compared to 1 injection of AMS.
Values are mean SE.
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kidney is followed by development of glomeruloscierosis, tub-
ulointerstitial fibrosis, persistent proteinuria and increased lev-
els of blood urea nitrogen. These findings implicate TGF-J31 in
the pathogenesis of progressive fibrosis in the kidney.
Methods
Experimental design
Anti-mesangial serum (AMS) was raised in New Zealand
white rabbits and prepared as described previously [11]. Male
Sprague-Dawley rats, weighing 150 g, were used. In each of two
experiments, 18 rats were divided into 3 groups of 6. On day 0,
groups 1 and 2 received 0.5 ml of AMS followed by 0.5 ml of
normal serum (as a source of complement); group 3 (control)
received 1.0 ml of normal serum. On day 7, group 1 received a
second injection of AMS and normal serum while groups 2 and
3 received an equal volume of normal serum.
Urinary protein was measured at 1, 3, 5, 10 and 18 weeks by
Bio-Rad protein assay (Bio-Rad Lab. Richmond, California,
USA) on 24-hour urine samples collected using metabolic
cages. Open renal biopsy was performed under anesthesia using
ketamine HC1, 10 mg/100 g body weight and xylazine 0.5 gIlOO
g body weight at 3, 5 and 10 weeks in six animals in each group.
At 18 weeks, after determination of serum levels of blood urea
nitrogen, rats were sacrificed under anesthesia and the kidneys
were excised. The kidney samples obtained at the time of
biopsy and at sacrifice were processed for light and immuno-
fluorescence microscopy and in situ hybridization. Renal his-
tology, expression of TGF-131 protein, TGF-f31 mRNA and
deposition of type I and III collagens were quantified. Extra-
cellular matrix markers of elevated TGF-/31 activity, including
an isoform of fibronectin containing extra domain A (fibronectin
EDA+), tenascin, biglycan and PAl-i were also examined. In
six animals in each group, open renal biopsy was not per-
formed, to control for the effect of biopsy on TGF-131 and
biglycan mRNA expression. Data from the first experiment
indicated that by 10 weeks both tubulointerstitial lesions and
progressive glomerular lesions were present in rats receiving
two injections of AMS. Therefore, animals in the second
experiment were sacrificed at five weeks under anesthesia to
study the expression of glomerular mRNA of TGF-fl1 and
biglycan before development of the tubulointerstitial lesions.
The glomeruli were isolated using the graded sieving technique,
total RNA was extracted and the levels of glomerular mRNA of
TGF-j31, biglycan and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH), were determined by Northern blotting.
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Fig. 3. Histological changes in experimental glomerulonephritis. Micrographs showing Masson Trichrome staining in glomerulonephritic and
control kidneys. (A) Kidney section from an animal 18 weeks after 2 injections of AMS and (B) higher power view of same section. Blue staining
is collagenous material indicating fibrosis. (C) Kidney section from animal 18 weeks after I injection of AMS and (D) control tissue. Magnification
ofA,CandD, X25OandB, x400.
Fig. 5. In situ hybridization of glomerulonephritic and control kidneys with a TGF-j31 antisense probe 18 weeks after induction of disease. Bright
field micrographs of a glomerulus (A) and tubulointerstitium (B) from a nephritic rat injected twice with AMS. The black grains indicate
hybridization of TGF-f31 mRNA. Comparable micrographs from an animal injected once with AMS (C) and (D) control. Magnification X400.
2.4 kb—
2.6kb—
1.5 kb—
a b
a
Yamamoto et a!: TGF-f31 in kidney fibrosis 919
U)
a)
E0
0)
a)0.
U)
a)
C.)
a)>
U)00.
L
C!:,
I—
Time, weeks
Fig. 6. Numbers of TGF-j31 positive cells in glomeruli. TGF-31 posi-
tive cells per glomerular cross section were quantitated in kidneys from
(dark bars) animals injected twice with AMS, (hatched bars) animals
injected once with AMS and (clear bars) control at 5 and 18 weeks after
induction of disease. * P < 0.01 compared to I injection of AMS and to
control; ** P < 0.01, 2 injections of AMS at 18 weeks compared to 5
weeks. Values are mean SE.
Fig. 4. Northern blotting of glomerular mRNA for TGF-/31 and bigly-
can in glomerulonephritic and control kidneys. Total RNA isolated
from glomeruli was hybridized with a cDNA probe to (A) TGF-f31, (B)
biglycan and (C) GAPDH, an enzyme constitutively expressed in the
rat. The blotting is 5 weeks after induction of disease in animals injected
twice with AMS (lane a), once with AMS (lane b) and control (lane c).
Molecular weight markers are shown to the left.
Histologic examination
Renal tissues were immediately fixed with 10% neutral buff-
ered formalin and embedded in paraffin. Two micrometer
sections were stained with Masson Trichrome. Twenty glomer-
uli were selected at random in coded sections prepared from
each animal and the degree of glomerular matrix accumulation
was determined as described previously [11]. Tubulointerstitial
lesions (matrix deposition and mononuclear cell infiltration)
were assessed in 20 randomly selected cortical areas per sample
observed at x 250 magnification using the following scale: 0 =
normal, 1 lesions involving less than 10% of the cortical area,
2 = involving 10 to 30%, 3 = involving 30 to 50% and 4 =
involving more than 50%.
Immunofluorescence microscopy was performed on tissues
snap frozen in cold isopentane. Four micrometer cryostat
sections were fixed in acetone and washed in PBS, pH 7.4.
TGF-/31 producing cells were detected using rabbit anti-TGF-/31
antibody (anti-LC) [19] provided by Dr. K.C. Flanders and Dr.
M.B. Sporn (National Institutes of Health, Bethesda, Mary-
land, USA). The deposition of extracellular matrix compo-
nents, type I and III collagens, fibronectin EDA+, tenascin
along with PAl- 1, were quantified in tissues obtained at 5 and 18
weeks. Primary antibodies used were goat anti-human type I
collagen and type III collagen (Southern Biotechnology Asso-
ciates, Birmingham, Alabama, USA), mouse monoclonal anti-
body to human fibronectin EDA+ [20], provided by Dr. L.
Zardi (Istituto Nazionale per Ia Ricerca sul Cancro, Italy),
rabbit anti-human tenascin (Telios, San Diego, California,
USA), rabbit anti-rat PAl-i (American Diagnostica, Green-
wich, Connecticut, USA). The secondary antibodies were
FITC-conjugated F(ab')2 donkey anti-rabbit IgO (Jackson Im-
munoresearch, West Grove, Pennsylvania, USA), FITC-conju-
gated rabbit anti-goat IgG (Cappel, Durham, North Carolina,
USA) and FITC-conjugated F(ab')2 rat anti-mouse IgG (Jack-
son Immunoresearch), Intraglomerular deposition of these ex-
tracellular matrix components was quantified by scoring 20
randomly selected glomeruli per sample on a 0 to 4 scale as
previously described [11]. The severity of interstitial matrix
deposition was evaluated according to the following scale in 20
randomly selected cortical areas per sample observed at X250
magnification: 0 = normal, 1 = deposition that involves less
5 18
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Fig. 7. Detection of TGF-131 protein in nephritic glomeruli. Immunofluorescence inicrographs of kidney sections stained with anti-TGF-pl
antibody. (A) Staining of a glomerulus (between arrows) from an animal 18 weeks after 2 injections of AMS. Note staining of many cells in
tubulointerstitium as well as in glomeruius. (B) Staining of a glomerulus (between arrows) from an animal 18 weeks after I injection of AMS.
Positive cells are confined to the glomerulus. The photographs were taken under identical conditions with equal exposures of 60 seconds.
Magnification x 250.
than 10% of the cortical area, 2 = involving 10 to 30%, 3 =
involving 30 to 50% and 4 = involving more than 50%.
To investigate the role of immune factors as an explanation
for progressive glomerulonephritis in animals receiving two
injections of AMS, intraglomerular deposition of rat IgG, 1gM,
IgA and C3 was detected using FITC-conjugated goat anti-rat
IgG, FITC-conjugated goat anti-rat 1gM (Jackson Immunore-
search), FITC-conjugated sheep anti-rat IgA (Binding Site, San
Diego, California, USA) and FITC-conjugated goat anti-rat C3
(Cappel), respectively.
In situ hybridization
Sections of formalin-fixed, paraffin-embedded kidneys ob-
tained at 18 weeks were subjected to in situ hybridization with
35S-cRNA murine probes that recognize rat TGF-1 mRNA.
The plasmid, pmTGF/31-A [21], was provided by Dr. H.L.
Moses (Vanderbilt University, Nashville, Tennessee, USA).
Antisense and sense cRNA riboprobes were generated after
digestion with restriction enzymes Hind III and Eco RI, respec-
tively. Riboprobes were labeled using 35S-UTP (Amersham,
Arlington Heights, Illinois, USA). Sections were rehydrated,
pretreated with 4% paraformaldehyde, proteinase K and acetic
anhydride. Riboprobes were added to a hybridization solution
containing 50% formamide, 0.3 M NaC1, 20 mx Tris, pH 8.0, 5
mM EDTA, 0.02% polyvinylpyrollidone, 0.02% Ficoll, 0.02%
bovine serum albumin, 10% dextran sulfate and 10 m dithio-
threitol. Hybridization was performed with 2 x iO cpmlml S
riboprobe added to each slide and incubated for 18 hours at
58°C. The slides were washed with Sx SSC at 50°C, 2x SSC at
65°C and treated with RNase A. Washing was then continued
with 2x SSC and 0.lx SSC at 52°C. Sections were next
dehydrated, dried and dipped in Kodak NTB-2 autoradio-
graphic emulsion. After exposure at 4°C for 18 days, the slides
were developed and counter-stained with hematoxylin/eosin.
Glomerular RNA preparation and Northern blotting
Total RNA was prepared from isolated glomeruli obtained at
five weeks and RNA blotting was carried out as described [11].
A mouse TGF-f31 cDNA probe, a 280 bp PvuII fragment that
was subcloned into Hind! digested pBluescript SKII+ (Strat-
agene, La Jolla, California, USA) from a mouse TGF-/31 cDNA
obtained from Dr. Derynck [21]. A human biglycan cDNA
probe, plasmid P16, was provided by Dr. L.W. Fisher (NIH)
[22]. A rat GAPDH cDNA probe [23] was a gift from Drs. P.
Kondaiah and M.B. Sporn (NIH). Autoradiography films were
scanned by laser densitometer (LKB, Bromma, Sweden). The
density of bands for GAPDH mRNA was used to control for the
differences in the total amount of mRNA loaded onto each gel
lane. For quantitative comparisons, the density of bands for
TGF-pl or tiglycan were divided by the density of bands for
GAPDH in the same lane. The resulting values were then
divided by the values for control animals (group 3). The data
presented, therefore, show the fold change of mRNA relative to
control animals. The mean values of two independent experi-
ments were determined.
Identification of TGF-/31 producing cells
Renal tissues stained with rabbit anti-TGF-j31 antibody (anti-
LC) and Lissamine Rhodamine-conjugated F(ab')2 donkey anti-
rabbit IgG (Jackson Immunoresearch) were double-stained with
one of the following mouse monoclonal antibodies and FITC-
conjugated F(ab')2 rat anti-mouse IgG (Jackson Irnmunore-
search): ED1 stains rat monocytes/macrophages (Serotec, Ox-
ford, UK); and 0X19 stains all T lymphocytes except natural
killer cells (Sera Lab, Sussex, UK). Cytoskeletal proteins of
interstitial mononuclear inflammatory cells were stained with
mouse monoclonal antibodies: anti-vimentin (GioGenex, San
Ramon, California, USA), anti-desmin (Dako, Carpinteria, Cal-
ifornia, USA) and anti-a-smooth muscle actin (Sigma). The
numbers of TGF-/31 positive cells, monocytes/macrophages and
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Fig. 8. Quantitation of deposition of extracellular matrix components
in glomerulonephritic and control kidneys. (A) Glomerular staining and
(B) tubulointerstitial staining scores 18 weeks after induction of disease.
Abbreviations are: collagens type I and III (COL I and COL III),
fibronectin EDA+ (FN EDA+), tenascin (TN) and plasminogen acti-
vator inhibitor-i (PA!-!). * P< 0.03 compared to control; ** P < 0.03
compared to 1 injection of AMS.
T lymphocytes per glomerulus were counted in 20 glomeruli
selected at random in the coded sections obtained at 5 and 18
weeks. The number of cells in glomeruli counted on frozen
sections has been reported to correlate adequately with that
obtained with the use of isolated glomeruli [24].
Statistical analysis
Differences between groups in values of proteinuria, blood
urea nitrogen, matrix score, the number of TGF-/31 positive
glomerular cells, monocytes/macrophages and T lymphocytes
were analyzed by t-test.
Results
Kidney histology, function and proteinuria
A single episode of glomerular immune injury in rats, result-
ing from one injection of AMS followed one week later by an
injection of normal serum, produced acute and self-limiting
mesangial proliferative glomerulonephritis as previously re-
ported [11]. Proteinuna increased transiently at one week and
then decreased to the level of control animals by three weeks
(Fig. 1). Renal histological findings showed a marked increase
in glomerular mesangial matrix at one week, which gradually
decreased toward normal, and was not significantly different
from control animals five weeks after the first AMS injection
(Fig. 2). No tubulointerstitial lesions occurred throughout this
study in glomerulonephritic rats given a single AMS injection or
in control rats injected twice with normal serum.
In contrast, in rats receiving two injections of AMS, one
week apart, urinary protein excretion increased significantly at
one week, remained elevated, and further increased at 10 and 18
weeks (Fig. 1). Histologically, a progressive buildup of glomer-
ular matrix, stained blue with Masson Trichrome, was noted
(Figs. 2 and 3). At 10 weeks focal tubulointerstitial lesions were
present, composed of increased amounts of extracellular matrix
and infiltrates of mononuclear cells; these lesions grew progres-
sively more severe by 18 weeks (Figs. 2 and 3).
The level of blood urea nitrogen at 18 weeks did not differ
significantly between rats receiving a single AMS injection and
control rats (mean SE; 23.4 0.3 vs. 22.7 0.4 mgldl,
respectively), but was significantly elevated in rats who re-
ceived two AMS injections (31.3 2.9 mg/dl, P < 0.025).
Expression of TGF-/31 mRNA and biglycan mRNA
cence as described below. We have previously shown that
glomerular TGF-f31 and biglycan production (a proteoglycan
whose synthesis is regulated by TGF-/3) are elevated four days
after a single AMS injection [7]. Figure 4 shows that the levels
of TGF-pl mRNA and biglycan mRNA, in the group injected
once with ATS, returned almost to control levels by five weeks.
However, animals receiving two AMS injections showed 2.5-
and 3.0-fold increases in the levels of glomerular TGF-/31
mRNA and biglycan mRNA, respectively, compared with
control animals at five weeks (Fig. 4). Furthermore, in situ
hybridization revealed a continued, remarkable increase of
TGF-/3l mRNA in glomeruli at 18 weeks (Fig. 5). In addition,
large numbers of mononuclear cells within the tubulointerstitial
lesions demonstrated strong TGF-pl mRNA expression (Fig.
5). Labeling of the control sense RNA probes was not increased
over background (result not shown).
Cells producing TGF-f31 protein in the nephritic kidney
The number of cells expressing TGF-131 protein increased
significantly in glomeruli of rats receiving two AMS injections
at five weeks. A further increase was noted at 18 weeks (P <
0.01) (Figs. 6 and 7) along with the appearance of a striking
number of mononuclear cells, stained positively for TGF-j31
protein, in the tubulointerstitial lesions (Fig. 7). Tubular cells
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* In kidney sections of control animals, mild expression of
TGF-f31 mRNA was found in glomeruli and vascular walls by in
situ hybridization, comparable to the normal distribution of
cells positive for TGF-j3l protein observed by immunofluores-
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Fig. 9. Immunofluorescence micrographs of glomerulonephritic and control kidneys. Kidney sections from an animal injected twice with AMS (A,
D, and C), once with AMS (B, E and H) and control (C, F and I) stained with and antibody to collagen type I (A, B and C), fibronectin EDA+
(D, E and F) and tenascin (U, H and 1)18 weeks after induction of disease. The photographs were taken under identical conditions with equal
exposures of 60 seconds. Magnification x250.
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Fig. 10. Double immunofluorescence staining of cells in glomerulonephritic kidneys. Tissue sections from animals 18 weeks after 2 injections of
AMS were double stained with (A, C and E) anti-TGF-/31, (B and D) an antibody that stains monocytes/macrophages and (F) an antibody that stains
T lymphocytes. The monocytes/macrophages (B, arrow) in a glomerulus and in the tubulointerstitium (D, arrows) are not positive for TGF-13l (A
and C, arrows). Likewise the T cells in the tubulointerstitium (F) are not positive for TGF-f3l (E). The photographs were taken under identical
conditions with equal exposures of 60 seconds. Magnification x400.
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Fig. 11. Double immunofluorescence staining of cells in the tubulointerstitium of nephritic animals 18 weeks after 2 injections of AMS. The tissue
sections were double stained with (A) anti-desmin, (C) anti-vimentin and (B and D) anti-TGF-J31. Many TGF-131 positive cells (B and D, arrows)
are also positive for desmin (A, arrows) and vimentin (C, arrows). The photographs were taken under identical conditions with equal exposures
of 60 seconds. Magnification x400.
surrounded by the mononuclear cells were also positive for
TGF-pl protein. TGF-pl positive cells per glomerulus did not
increase in animals receiving a single AMS injection or in
control animals at 5 or 18 weeks, and in the tubulointerstitium
of these rats, TGF-f31 positive cells were detected only in
vascular walls.
Extracellular matrix deposition in the kidney
Matrix scores of glomerular and tubulointerstitial deposition
of type I and III collagens, fibronectin EDA+, tenascin and
PAl-i, at 18 weeks are presented in Figure 8. Representative
immunofluorescence micrographs of kidney tissue at 18 weeks
are shown in Figure 9.
In control animals, type I and type III collagens were found
only in sparse amounts in the tubulointerstitium, but not in
glomeruli. Trace amounts of fibronectin EDA+, tenascin and
PAT-i were detected only in the glomerular mesangium. At 18
weeks, a weak irregular staining of tenascin was seen in some
tubulointerstitial regions and areas surrounding Bowman's cap-
sule.
Intraglomerular deposition of type I and type III collagens
was noted in both groups of rats treated with AMS as early as
one week after the first AMS injection. At five weeks, there was
significantly more glomerular accumulation of all matrix com-
ponents measured in both AMS groups compared to control
animals (result not shown). However, matrix scores for all
components were significantly higher in animals receiving two
injections of AMS compared to those receiving one injection.
By 18 weeks, intraglomerular deposition of matrix components
had decreased toward control values in the group given one
injection of AMS but continued to increase in rats given two
injections (Fig. 8). Also, there was a marked deposition of all
matrix components in the tubulointerstitial lesions at 18 weeks
in the group given two AMS injections (Figs. 8 and 9).
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No deposits of rat IgG, IgA and C3 were found in any animals
except for occasional absorption droplets containing rat IgG
and/or IgA at 18 weeks. A small amount of mesangial deposition
of rat 1gM was observed in control rats and rats given one AMS
injection at 18 weeks; a slightly increased amount of mesangial
1gM deposition was noted in areas of glomerulosclerosis in
animals receiving two AMS injections.
Identification of TGF-f31 producing cells
The number of monocytes/macrophages and T lymphocytes
were determined in kidney sections from all rats in each group
using antibodies specific for each cell type. Nephritic glomeruli
from animals injected twice with AMS contained higher num-
bers of monocytes/macrophages than did glomeruli from the
other two groups; however, this number was an average of
three monocytes/macrophages per glomerular cross section at
five weeks and two at 18 weeks (result not shown). And no
glomerulus in any group contained more than one T lymphocyte
per glomerular section. As shown in Figure 6 the average
number of TGF-f31 positive cells per glomerular cross section in
animals in all three groups was at least 25 or higher. Thus the
majority of TGF-/31 positive cells are likely to be resident
glomerular cells. Double immunofluorescence staining con-
firmed our opinion that the majority of monocytes/macrophages
and T lymphocytes that were detected in the nephntic kidney at
18 weeks were not TGF-f31 positive (Fig. 10); this finding does
not exclude the possibility that some monocytes/macrophages
and T lymphocytes, positive for TGF-f31, were overlooked.
However, many of the TGF-/31 positive cells in the tubuloin-
terstitial lesions in rats receiving two AMS injections were also
positive for vimentin, desmin and/or a-smooth muscle actin
(Fig. 11). This double-staining result suggests that these cells
are in the fibroblast/myofibroblast lineage [25].
Discussion
Extensive studies of experimental glomerulonephritis (acute
and chronic serum sickness) have shown that the kidney can
recover from a single episode of immune injury, but that
repeated or multiple episodes of immune injury lead to chronic,
progressive disease with fibrosis and kidney failure [26—29]. The
same seems true in human disease. Acute postinfectious gb-
merubonephritis, due to a single period of immune injury, is
reversible; whereas, continued immune injury as in lupus
nephritis produces chronic disease and kidney failure [30, 31].
The glomerulonephritis induced by injection of AMS also
conforms to this pattern of injury. A single injection of AMS
into rats produces an acute self-limiting glomerubonephritis
without affecting the tubulointerstitium of the kidney as shown
in this study and by others [12, 13]. In another report, kidney
tissue examined up to nine months after animals received one
injection of AMS was normal compared to control [32]. In the
single injection model, we have shown previously that TGF-/31
plays a crucial role in the pathological accumulation of extra-
cellular matrix in gbomeruli [11, 15]. Intraglomerular expression
of TGF-131 protein and TGF-J31 mRNA increased, peaked at
seven days, and then gradually decreased toward control levels
in four weeks, paralleling both mesangial matrix expansion and
enhanced proteoglycan and fibronectin production in nephritic
glomeruli. The present study demonstrates the same result; the
number of cells producing TGF-/31 protein and the level of
TGF-131 mRNA in glomeruli is no longer elevated five weeks
after a single injection of AMS.
In contrast, two episodes of glomerular injury induced by
injections of AMS given one week apart produces progressive
gbomerular disease characterized by elevated levels of urinary
protein and blood urea nitrogen. Accompanying the functional
changes is the persistence of pathological matrix accumulation
in the glomeruli. However, the most important finding in our
study is the development of lesions in the tubulointerstitium of
the kidney—an event that does not occur following a single
injection of AMS. Furthermore, the tubulointerstitial disease is
also progressive as evidenced by continued matrix accumula-
tion. Thus the sequence of pathological changes in the model
mimics the findings in humans where chronic glomerular dis-
ease precedes the development of tububointerstitial lesions [3].
Another similarity between the model and human disease is the
accumulation of collagens type I and III in the nephritic
glomeruli and tubulointerstitial lesions. These collagens are
absent in normal rat and human gbomeruli and are found only in
small amounts in the tububointerstitium. In human disease, and
as shown in this report, the deposition of collagens type I and
III is correlated with the histological development of glomeru-
boscierosis and tububointerstitial fibrosis [2, 10, 33, 34]. Of
interest is that the production of collagens by cultured cells is
induced by TGF-131 [35, 36].
Following the second AMS injection persistent increases in
glomerular TGF-f31 mRNA and TGF-/31 protein expression
were noted which paralleled the progressive gbomerular accu-
mulation of type I and III collagens, fibronectin EDA+, tena-
scm and the elevated levels for biglycan mRNA. An important
feature of these findings is that while other cytokines may also
stimulate the production of collagens, fibronectin EDA+, ten-
ascin and biglycan are relatively specifically induced by
TGF-f31 and are considered tissue markers of TGF-/31 activity
[20, 37, 38, 39]. Furthermore, the appearance of tubulointersti-
tial lesions was heralded by a marked infiltration of mononu-
clear cells expressing elevated levels of TGF-f3l mRNA and
TGF-f31 protein. In another model of kidney injury, induced by
repeated injections of aminonucleoside of puromycin, a chem-
ical toxic to the glomerulus, increased TGF-f31 expression was
also detected in association with the development of tubuloin-
terstitial fibrosis [40]. These data, along with our previous
findings, strongly suggest that increases in TGF-f31 expression
underlie the increased synthesis and deposition of these extra-
cellular matrix components.
In addition to enhanced synthesis of matrix components,
inhibition of matrix degradation could facilitate the accumula-
tion of extracellular matrix in tissues. TGF-13 is known to
decrease the synthesis of proteases and increase the synthesis
of protease inhibitors [41—43]. The plasmin protease system has
been implicated in matrix degradation. Plasmin is a serine
protease known for its activity against fibrin but which is also
capable of degrading extracellular matrix [44]. PAl- I is a potent
inhibitor of plasminogen activators that convert plasminogen to
plasmin. We have recently found that after a single administra-
tion of AMS, PAl-i synthesis and deposition into gbomerular
matrix are dramatically increased [14]. In the present study,
PAl- 1 deposition into both glomerular and tubulointerstitial
lesions was increased in rats receiving two injections of AMS
compared to the one injection group and control, This suggests
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that not only elevated extracellular matrix production but also
suppression of matrix degradation, both likely mediated by
TGF-/31, play a role in extracellular matrix accumulation in this
model of progressive kidney fibrosis.
Early accumulation of platelets and macrophages in damaged
glomeruli has been reported in acute glomerulonephritis in-
duced by a single AMS injection [32, 45] and likely contributes
to the elevated levels of TGF-f3l in the initial phase of disease
[46, 47]. However, the intraglomerular localization of platelets
and macrophages in the single ATS model is transient, peaks on
day 1, and does not coincide with the later increase in glomer-
ular TGF-131 expression. T lymphocytes can also produce
TGF-/31 [48]. However, we found that the number of intraglom-
erular monocytes/macrophages and T lymphocytes was only
about 10 percent of the total number of TGF-131 positive cells.
Also, in double staining studies at 18 weeks, monocytes/
macrophages and T lymphocytes were not TGF-f3l positive.
The interstitial cells producing TGF-f31 were positive for vimen-
tin, desmin and/or a-smooth muscle actin, suggesting a fibro-
biastic/myofibroblastic phenotype [25]. These results support
the idea that resident glomerular cells and interstitial fibroblas-
tic/myofibroblastic cells are largely responsible for the sus-
tained, elevated expression of TGF-pl seen in animals follow-
ing the second injection of AMS.
No intraglomerular deposition of rat IgG, IgA and C3 was
observed throughout this study. Thus we found no evidence
that the progressive kidney disease following two AMS injec-
tions was attributable to an autologous immune response to
AMS proteins or to structural glomerular antigens. Some gb-
meruli from animals receiving two AMS injections did show
small deposits of rat 1gM in focal areas of sclerosis at 18 weeks.
However, 1gM deposits are commonly found in sclerotic and/or
hyalinotic glomerular lesions in both human and experimental
glomerulonephritis and are thought to be due to nonspecific
trapping and not immune complex formation [49, 50].
In this model increased expression of gbomerular TGF-/3l
protein and TGF-/31 mRNA occurred before tubulointerstitial
lesions developed. The first evidence of tubulointerstitial in-
volvement was the appearance of mononuclear cells in the
interstitium adjacent to diseased glomeruli, suggesting that
TGF-f31 released from the nephritic glomeruli may act as a
chemoattractant. TGF-$1 is a known chemoattractant for
monocytes/macrophages [51] and fibroblasts [521 and is capable
of inducing its own production by target cells [53]. TGF-f31
produced by the glomerulus may reach the tubulointerstitium
by direct diffusion, tubular reabsorption of the glomerular
ultrafiltrate or in the blood via peritubular capillaries.
Our findings support the concept that, following repeated
episodes of glomerular injury, gbomerular-derived TGF-/3l may
activate tubulointerstitial cells to produce TGF-f31. The sus-
tained expression of TGF-f31 by glomerular and tubulointersti-
tial cells then leads to extracellular matrix deposition and the
development of progressive kidney fibrosis. At present it is
unknown why TGF-/31 expression is self-limited following one
injection of AMS but persists following two AMS injections. It
has been hypothesized that a failure to shut down TGF-f3
production, due to a defect in TGF-/3 regulation or repeated
injury, may lead to a vicious circle of continued production of
TGF-p and extracellular matrix [54]. Our results suggest the
presence of a vicious circle of TGF-fll production in the kidney.
Previously we have shown that anti-TGF-/31 and the proteogly-
can decorin can effectively suppress glomerular matrix deposi-
tion following a single injection of AMS [15, 55]. It is unknown
whether antagonists of TGF-/31 might block or suppress
TGF-/31 production and prevent the development of progres-
sive fibrosis in the current model. Future studies will investigate
this important question.
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